sur Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Appoints Dr. Michael Lock to Advisory Board
Onco-Innovations Limited has announced the appointment of Dr. Michael Lock to its Scientific and Clinical Advisory Board. With his extensive expertise in clinical trial design and multidisciplinary cancer care, Dr. Lock will support the company's development of innovative therapies, including the PNKP inhibitor program.
Dr. Lock, a Professor at Western University, has held significant roles in oncology leadership, such as Medical Director of the London Regional Cancer Program. His contributions to oncology, both internationally and domestically, have been recognized with awards like the Human Touch Award.
Thomas O'Shaughnessy, CEO of Onco-Innovations, emphasized Dr. Lock's valuable role in advancing the company's clinical development initiatives.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Onco-Innovations Limited